2.3 C
Thursday, December 1, 2022
- Advertisement -


Eli Lilly and Co

What increasing confidence in Biogen’s latest Alzheimer’s drug means for Eli Lilly

Wall Street increasingly believes U.S. drug regulators will approve Biogen 's (BIIB) latest experimental Alzheimer's treatment following the release of detailed late-stage clinical trial...

Jim Cramer’s top 10 things to watch in the market Wednesday: Fed’s Powell, data on Alzheimer’s drug, tech earnings

It's the last day of November, and the Dow and S&P 500 are poised to log their second straight month of gains. Source link

How we’re thinking about our Club stock exposure to China following Covid protests

Global stocks slumped Monday on growing concerns about intensifying protests across China over the communist government's strict Covid policies. Wall Street was not immune:...

Elon Musk has himself to blame for Twitter’s advertising woes, civil rights groups say

Leaders of major civil rights groups are denying accusations made by Elon Musk, who said they broke an agreement with him by encouraging companies...

FDA agrees to expedited review of Eli Lilly’s obesity drug. Here’s where we stand on the stock

While we expected fast-track approval, Thursday's news is still positive because it offers more clarity on the obesity drug's consideration timeline. Source link

Latest news

- Advertisement -